From: Perspectives for improvement of Mycoplasma hyopneumoniae vaccines in pigs
Antigen | Vector | Route | Number of vaccinations | Significant decrease of | Humoral response | CMI responsea | Other/comments | References | |||
---|---|---|---|---|---|---|---|---|---|---|---|
Lung lesions | Clinical signs | M. hyopneumoniae numbers | Serum | BALFb | |||||||
NrdF (R2) | S. Typhimurium aroA SL3261c | Oral | 2 | Yes | Â | Â | No | IgA | Yes | Higher ADGb; IgA only after challenge | [94] |
P97 (R1R2) | E. rhusiopathiae strain YS-19c | Intranasal | 2 | Yes | Â | Yes | No | Â | Yes | Â | [95] |
P97 (R1R2) | E. rhusiopathiae strain Koganei 65–0.15 | Oral | 3 | Yes |  | No | IgG | IgA | Yes | IgG and IgA only after challenge | [96] |
P97 (R1R2) | Adenovirus | Intranasal | 2 | Yes | Â | Yes | IgG, IgA | IgA, IgG (saliva) | Yes | higher ADG; serum inhibited M. hyopneumoniae growth; minor decrease of lung inflammation Commercial vaccine: no anti-P97 antibodies, better protection | [97] |